REPL today
$21.89-$0.09 (-0.41%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minSymmetric Triangle
Daily trend turns up above $13.83
Key levels
Resistance$25.06
Resistance$23.54
Support$21.32
Support$19.44
Latest news & SEC filings
AnalystLeerink Partners kept its Outperform rating on Replimune (REPL) and raised its price target to $31 from $17.
All REPL news →About Replimune
Replimune is a biotech firm in the clinical testing phase that creates virus-based cancer treatments. Its main candidate, RP1, uses a modified form of the herpes virus to destroy malignant cells and spark the body's defenses against tumors, and is under study for skin cancers such as advanced melanoma. The company is also developing RP2 and RP3 for other cancers, including those of the liver and lungs. These treatments are injected straight into solid tumors and tested alone and alongside checkpoint inhibitors.
Based on the company's 10-K filed Jun 29, 2026.
Nasdaq · Healthcare
Replimune Group, Inc. (REPL)
What Is the Price Target for REPL?
SEPT Low Target
$19.00
SEPT Mid Target
$27.00
SEPT High Target
$31.00
Analyst Consensus
$27.00
Is REPL a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for REPL.
Start Free Trial →Is REPL Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$21.48
4
Moat Score
NONE
1/9
Piotroski Score
-1.2
Altman Z-Score
What Is Smart Money Doing with REPL?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SLATTERY JOSEPH P | director | Sale | 5,200 | $113K | Nov 9, 2026 |
| Dhingra Kapil | director | Buy | 43,169 | $76K | Nov 2, 2026 |
| Dhingra Kapil | director | Sale | 21,500 | $409K | Nov 2, 2026 |
| Astley-Sparke Philip | director | Sale | 50,000 | - | Aug 20, 2026 |
| Sarchi Christopher | officer | Sale | 12,000 | $111K | Jun 1, 2026 |
| Xynos Konstantinos | officer | Sale | 14,023 | $71K | May 18, 2026 |
| Schwendenman Andrew | officer | Sale | 7,894 | $40K | May 18, 2026 |
| Sarchi Christopher | officer | Sale | 8,626 | $44K | May 18, 2026 |
| Astley-Sparke Philip | director | Sale | 17,657 | $90K | May 18, 2026 |
| Patel Sushil | director officer | Sale | 37,324 | $190K | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →REPL Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-10.1%
FCF Growth YoY
-43.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for REPL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for REPL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:25 | $21.89 | 4,331 | $$95K | SELL |
| 21:00:13 | $21.89 | 102,556 | $$2.2M | SELL |
| 21:00:13 | $21.89 | 1,300 | $$28K | SELL |
| 21:00:13 | $21.89 | 2,085 | $$46K | SELL |
| 21:00:13 | $21.89 | 5,866 | $$128K | SELL |
5 dark pool trades shown · $$2.5M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Replimune Group, Inc. (REPL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →REPL — frequently asked questions
What is REPL stock price today?
Replimune Group, Inc. (REPL) is at $21.89, down 0.41% (-$0.09) at the Nov 13, 2026 close.
Why is REPL stock moving today?
Latest REPL news — Oct 29, 2026: Leerink Partners kept its Outperform rating on Replimune (REPL) and raised its price target to $31 from $17.
What is the REPL price target?
The average analyst price target for REPL is $27.00, ranging from $19 to $31, based on 3 analysts. Latest: JP Morgan raises on Oct 30, 2026.
What do analysts rate REPL?
Analyst ratings for REPL: 3 Buy, 6 Hold, 6 Sell — consensus Hold.
Did REPL beat earnings?
REPL last reported on Oct 28, 2026: EPS -$0.54 vs -$0.78 expected — a beat of 31.1%.
Does REPL pay a dividend?
REPL does not currently pay a dividend.
What are REPL support and resistance levels?
Support: $21.32, $19.44, $18.07. Resistance: $23.54, $25.06, $28.03.
What are insiders doing with REPL?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on REPL?
Oct 29, 2026: Leerink Partners kept its Outperform rating on Replimune (REPL) and raised its price target to $31 from $17.